5 hospitals approved to join WHOs Solidarity Trial to find treatment for COVID-19

Published On 2020-05-11 09:11 GMT   |   Update On 2020-05-11 09:11 GMT
Advertisement

New Delhi  - Five hospitals, two from Ahmedabad and one each from Chennai, Jodhpur and Bhopal, have so far been approved to conduct randomised controlled clinical trials under WHO''s Solidarity Trial to find an effective treatment for COVID-19.

The hospitals, including the AIIMS in Jodhpur, Apollo Hospital in Chennai and the B J Medical College and Civil Hospital in Ahmedabad, will be conducting clinical trials on four treatment protocols — remdesivir, combination of lopinavir and ritonavir, hydroxychloroquine and lopinavir and ritonavir with Interferon beta-1a.

Read Also:  COVID-19: Can disabled candidate appear for PG medical Counselling without disability certificate? Delhi HC asks MCI, Centre

According to Dr Sheela Godbole, national coordinator of the WHO-India Solidarity Trial and head of the Division of Epidemiology at ICMR-National AIDS Research Institute, there is a plan to enrol at least 20 clinical sites across India.

The clinical trials on any of the treatment protocols would be discontinued if it showed any adverse effects on any of the patients, Godbole said.

The health facilities need to get regulatory approval from the Drug Controller General of India (DCGI) and have to be registered on the Clinical Trial Registry of India (CTRI) for this.

Four of the hospitals have already begun the trial.

"We want as many patients as possible to be quickly enrolled in the randomised controlled clinical trial so that results also can come out soon," she said, adding the sample size has to be at least 1,500 in total from all clinical sites.

Patients are being enrolled in several countries in these clinical trials to generate enough strong evidence on their efficacy to treat COVID-19 patients, Godbole said.

"The Solidarity Trial aims to rapidly discover whether any of the drugs slows the disease''s progression or improves survival. Other drugs can be added based on emerging evidence," she said.

Godbole further said the drug remdesivir and Interferon beta-1a have been provided by the global health body to India to conduct clinical trials. US-based pharma company Gilead Sciences has donated the antiviral drug to the WHO.

Over 100 countries are working together to find effective therapeutics as soon as possible, via the Trial, according to the WHO website.

The global data safety and monitoring boards will periodically be reviewing the trials and accordingly, inform the WHO. 

Read Also:  Non Bailable warrant against Delhi MLA named in doctor's suicide note


Tags:    
Article Source : PTI

Disclaimer: This website is primarily for healthcare professionals. The content here does not replace medical advice and should not be used as medical, diagnostic, endorsement, treatment, or prescription advice. Medical science evolves rapidly, and we strive to keep our information current. If you find any discrepancies, please contact us at corrections@medicaldialogues.in. Read our Correction Policy here. Nothing here should be used as a substitute for medical advice, diagnosis, or treatment. We do not endorse any healthcare advice that contradicts a physician's guidance. Use of this site is subject to our Terms of Use, Privacy Policy, and Advertisement Policy. For more details, read our Full Disclaimer here.

NOTE: Join us in combating medical misinformation. If you encounter a questionable health, medical, or medical education claim, email us at factcheck@medicaldialogues.in for evaluation.

Our comments section is governed by our Comments Policy . By posting comments at Medical Dialogues you automatically agree with our Comments Policy , Terms And Conditions and Privacy Policy .

Similar News